- Exchanges
- BSE, NSE
- Industry
- Specialty Chemicals
- Issue
- Book building
Sudeep Pharma IPO
₹774.15
+30.55% on listing
Listing-day close · NSE · 28 Nov 2025 · issue price ₹593
Sudeep Pharma’s ₹895 crore IPO was priced at ₹593 a share. It listed on the NSE on 28 Nov 2025 and closed its first day at ₹774.15, up 30.55% on the issue price.
Timeline
- Opens
- Closes
- Allotment
- Refunds
- Shares in demat
- Listing
Issue details
- Issue size
- ₹895 Cr
- Fresh issue
- ₹95 Cr
- Offer for sale
- ₹800 Cr
- Lot size
- 25 shares
- Minimum investment
- ₹14,825
- Face value
- ₹1
- Registrar
- MUFG Intime India
Subscription
| Category | Shares offered | Times subscribed |
|---|---|---|
| Total | — | 65.56× |
Overall, from the basis of allotment.
Financials and valuation
- Market cap (post-issue)
- ₹6,698 Cr
- P/E (post-issue)
- 53.5
- EPS (post-issue)
- ₹11.07
- Price to book
- 12.9
- Debt to equity
- 0.20
- EBITDA margin
- 39.70%
- PAT margin
- 27.63%
- Promoter holding
- 89.37% → 76.15%
Financials as of 31 Mar 2025, from the offer documents.
Listing
- Listing date
- 28 Nov 2025
- Issue price
- ₹593
- Open
- ₹730.00
- High
- ₹795.00
- Low
- ₹725.00
- Close
- ₹774.15
Listing day on the NSE. The close was +30.55% on the issue price.
FAQs
When did the Sudeep Pharma IPO open and close?
It opened on 21 Nov 2025 and closed on 25 Nov 2025.
What was the Sudeep Pharma IPO price?
The price band was ₹563–593 a share. The final issue price was ₹593.
What is the lot size and minimum investment?
One lot is 25 shares, ₹14,825 at ₹593 a share. Retail investors apply in whole lots.
How much did Sudeep Pharma raise?
₹895 crore: ₹95 crore of new shares and ₹800 crore offered by existing shareholders.
How many times was the Sudeep Pharma IPO subscribed?
65.56 times overall.
How did Sudeep Pharma list?
It listed on the NSE on 28 Nov 2025 at ₹730.00 and closed the day at ₹774.15, up 30.55% on the ₹593 issue price.
Who is the registrar of the Sudeep Pharma IPO?
MUFG Intime India handles the allotment, refunds and credit of shares.
For information only. Not investment advice or a research report.
Full disclaimerSee how an IPO fits your plan
Armor checks every holding against your goals, risk and timeline.
Get the app